Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

References

• Drucker DJ The role of gut hormones in glucose homeostasis J Clin Invest 2007 117 24 32 17200703
   PubMed Web of Science ®Google Scholar
• Meier JJ Nauck MA Incretins and the development of type 2 diabetes Curr Diab Rep 2006 6 194 201 16898571
   PubMedGoogle Scholar
• Holst JJ The physiology of glucagon-like peptide 1 Physiol Rev 2007 87 1409 1439 17928588
   PubMed Web of Science ®Google Scholar
• Kreymann B Williams G Ghatel MA Bloom SR Glucagon-like peptide-1 7–36: a physiological incretin in man Lancet 1987 2 1300 1304 2890903
   PubMed Web of Science ®Google Scholar
• McIntosh CH Widenmaier S Kim SJ Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP) Vitam Horm 2009 80 409 471 19251046
   PubMed Web of Science ®Google Scholar
• Seino Y Fukushima M Yabe D GIP and GLP-1, the two incretin hormones: similarities and differences J Diabet Invest 2010 1 8 23
   PubMed Web of Science ®Google Scholar
• Herman GA Bergman A Stevens C Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes J Clin Endocrinol Metab 2006 91 4612 4619 16912128
   PubMed Web of Science ®Google Scholar
• Karasik A Aschner P Katzeff H Davies MJ Stein PP Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials Curr Med Res Opin 2008 24 489 496 18182122
   PubMed Web of Science ®Google Scholar
• Xu L Man CD Charbonnel B Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach Diabetes Obes Metab 2008 10 1212 1220 18476982
   PubMed Web of Science ®Google Scholar
• Brazg R Xu L Dalla Man C Cobelli C Thomas K Stein PP Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes Diabetes Obes Metab 2007 9 186 193 17300594
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Deacon CF Ahrén B Holst JJ Inhibitors of depeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004 13 1091 1102
   PubMed Web of Science ®Google Scholar
• Drucker DJ Therapeutic potential of depeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes Expert Opin Investig Drugs 2003 12 87 100
   PubMed Web of Science ®Google Scholar
• Dicker D DPP-4 inhibitors. Impact on glycemic control and cardiovascular risk factors Diabetes Care 2011 34 Suppl 2 S276 S278 21525468
   PubMed Web of Science ®Google Scholar
• Davidson JA Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors Cleve Clin J Med 2009 76 Suppl 5 S28 S38 19952301
   PubMedGoogle Scholar
• Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 2007 298 194 206 17622601
   PubMed Web of Science ®Google Scholar
• Balas B Baig MR Watson C The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients J Clin Endocrinol Metab 2007 92 4 1249 1255 17244786
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Round E Swern AS Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis BMC Endocr Disord 2008 8 14 18954434
   PubMedGoogle Scholar
• Karagiannis T Paschos P Paletas K Matthews DR Tsapas A Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 2012 344 e1369 22411919
   PubMed Web of Science ®Google Scholar
• Baetta R Corsini A Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences Drugs 2011 71 1441 1467 21812507
   PubMed Web of Science ®Google Scholar
• Yoshida T Akahoshi F Sakashita H Discovery and preclinical profile of teneligliptin(3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Bioorg Med Chem 2012 20 19 5705 5719 22959556
   PubMed Web of Science ®Google Scholar
• Eto T Inoue S Kadowaki T Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 2012 14 1040 1046 22776014
   PubMed Web of Science ®Google Scholar
• Kadowaki T Kondo K Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus Diabetes Obes Metab Epub 3 6 2013
   Web of Science ®Google Scholar
• Monami M Lamanna C Desideri CM Mannucci E DPP-4 inhibitors and lipids: systematic review and meta-analysis Adv Ther 2012 29 14 25 22215383
   PubMed Web of Science ®Google Scholar
• Poitout V Robertson RP Glucolipotoxicity: fuel excess and beta-cell dysfunction Endocrine Rev 2008 29 351 366 18048763
   PubMed Web of Science ®Google Scholar
• Sone H Tanaka S Tanaka S Japan Diabetes Complications Study Group Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS) J Clin Endocrinol Metab 2011 96 3448 3456 21865372
   PubMed Web of Science ®Google Scholar
• Ansar S Koska J Reaven PD Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins Cardiovasc Diabetol 2011 10 61 21736746
   PubMed Web of Science ®Google Scholar
• Hsieh J Longuet C Baker CL The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice Diabetologia 2010 53 552 561 19957161
   PubMed Web of Science ®Google Scholar
• Matikainen N Mänttäri S Schweizer A Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 2006 49 2049 2057 16816950
   PubMed Web of Science ®Google Scholar
• Tremblay AJ Lamarche B Deacon CF Weisnagel SJ Couture P Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes Diabetes Obes Metab 2011 13 366 373 21226820
   PubMed Web of Science ®Google Scholar
• Fukuda-Tsuru S Anabuki J Abe Y Yoshida K Ishii S A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations Eur J Pharmacol 2012 696 1–3 194 202 23022337
   PubMed Web of Science ®Google Scholar
• Ionescu E Sauter JF Jeanrenaud B Abnormal oral glucose tolerance in genetically obese (fa/fa) rats Am J Physiol 1985 248 E500 E506 3887938
   PubMed Web of Science ®Google Scholar
• Pederson RA White HA Schlenzig D Pauly RP McIntosh CH Demuth HU Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide Diabetes 1998 47 1253 1258 9703325
   PubMed Web of Science ®Google Scholar
• Wøjdemann M Wettergren A Sternby B Inhibition of human gastric lipase secretion by glucagon-like peptide-1 Dig Dis Sci 1998 43 799 805 9558037
   PubMed Web of Science ®Google Scholar
• Qin X Shen H Liu M GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats Am J Physiol Gastrointest Liver Physiol 2005 288 G943 G949 15677555
   PubMed Web of Science ®Google Scholar
• Mahler R Statford WS Tarrant ME Ashmore J The effect of insulin on lipolysis Diabetes 1964 13 297 302 14166680
   PubMed Web of Science ®Google Scholar
• Moritoh Y Takeuchi K Asakawa T Kataoka O Odaka H Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice Br J Pharmacol 2009 157 415 426 19371350
   PubMed Web of Science ®Google Scholar
• Mu J Woods J Zhou YP Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes Diabetes 2006 55 1695 1704 16731832
   PubMed Web of Science ®Google Scholar
• Pospisilik JA Martin J Doty T Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 2003 52 741 750 12606516
   PubMed Web of Science ®Google Scholar
• Sudre B Broqua P White RB Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats Diabetes 2002 51 1461 1469 11978643
   PubMed Web of Science ®Google Scholar
• Pugh RN Murray-Lyon IM Dawson JL Pietroni MC Williams R Transection of the esophagus for bleeding esophageal varices Br J Surg 1973 60 646 654 4541913
   PubMed Web of Science ®Google Scholar
• Goldstein BJ Feinglos MN Lunceford JK Johnson J Williams-Herman DE Sitagliptin 036 Study Group Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 2007 30 1979 1987 17485570
   PubMed Web of Science ®Google Scholar
• Scheen AJ A review of gliptins in 2011 Expert Opin Pharmacother 2012 13 81 99 22149369
   PubMed Web of Science ®Google Scholar
• Barnett A Allsworth J Jameson K Mann R A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies Curr Med Res Opin 2007 23 1493 1507 17559747
   PubMed Web of Science ®Google Scholar
• Koliaki C Doupis J Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology Adv Ther 2012 29 12 993 1004 23184570
   PubMed Web of Science ®Google Scholar
• Genovese S Tedeschi D Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization Adv Ther 2013 30 2 152 164 23430354
   PubMed Web of Science ®Google Scholar
• Narita T Katsuura Y Sato T Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients Diabet Med 2009 26 187 188 19236625
   PubMed Web of Science ®Google Scholar
• Arakawa M Ebato C Mita T Miglitol suppresses the postprandial increases in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects Metabolism 2008 57 1299 1306 18702958
   PubMed Web of Science ®Google Scholar
• Lee A Patrick P Wishart J Horowitz M Morley JE The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics Diabetes Obes Metab 2002 4 329 335 12190996
   PubMed Web of Science ®Google Scholar
• Narita T Yokoyama H Yamashita R Comparison of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients Diabetes Obes Metab 2012 14 283 287 22051162
   PubMed Web of Science ®Google Scholar
• Aoki K Kamiyama H Yoshimura K Shibuya M Masuda K Terauchi Y Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin Acta Diabetol 2012 49 225 230 21898126
   PubMed Web of Science ®Google Scholar
• Gross TM Bode BW Einhorn D Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use Diabetes Technol Ther 2000 2 49 56 11467320
   PubMedGoogle Scholar
• Kaufman FR Gibson LC Halvorson M Carpenter S Fisher LK Pitukcheewanont P A pilot study of glucose measurements using the glucose sensor Diabetes Care 2002 25 1185 1191 12087017
   PubMed Web of Science ®Google Scholar
• Kishimoto M Noda M A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers Cardiovasc Diabetol 2011 10 115 22189184
   PubMed Web of Science ®Google Scholar
• Scheen AJ DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials Diabetes Metab 2012 38 2 89 101 22197148
   PubMed Web of Science ®Google Scholar
• Defronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Mikhail N Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential Vasc Health Risk Manag 2008 4 1221 1227 19337535
   PubMedGoogle Scholar
• Rosenstock J Kim SW Baron MA Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes Diabetes Obes Metab 2007 9 2 175 185 17300593
   PubMed Web of Science ®Google Scholar
• Mäkimattila S Nikkilä K Yki-Järvinen H Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus Diabetologia 1999 42 406 412 10230643
   PubMed Web of Science ®Google Scholar
• Kishimoto M Noda M Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes Diabetes Ther 2012 3 1 11 23055336
   PubMedGoogle Scholar
• Vilsbøll T Rosenstock J Yki-Järvinen H Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Diabetes Obes Metab 2010 12 167 177 20092585
   PubMed Web of Science ®Google Scholar
• Fonseca V Schweizer A Albrecht D Baron MA Chang I Dejager S Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes Diabetologia 2007 50 1148 1155 17387446
   PubMed Web of Science ®Google Scholar
• Foley JE Ligueros-Saylan M He YL Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes Horm Metab Res 2008 40 727 730 18597213
   PubMed Web of Science ®Google Scholar
• iPro®2 Professional CGM [homepage on the internet] Medtronic MiniMed Inc 2013 Available from: http://www.professional.medtronicdiabetes.com/hcp-products/ipro2 Accessed March 29, 2013
   Google Scholar